JW Therapeutics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A pioneer in CAR-T cell therapy in China, with a commercially approved product for lymphoma.
OncologyHematology
Technology Platform
An integrated platform for autologous CAR-T cell therapy development and manufacturing, with research into next-generation allogeneic approaches.
Opportunities
Significant growth potential in expanding CAR-T therapy to earlier lines of treatment, new cancer types, and broader patient access in China.
Risk Factors
High treatment costs, complex logistics, and safety concerns (like CRS) may limit market penetration and adoption.
Competitive Landscape
Leads the nascent but fiercely competitive Chinese CAR-T market, contending with other domestic leaders like Fosun Kite and global giants.